Development of new pyrrolopyrimidine-based inhibitors of Janus kinase 3 (JAK3).

Article Details

Citation

Copy to clipboard

Clark MP, George KM, Bookland RG, Chen J, Laughlin SK, Thakur KD, Lee W, Davis JR, Cabrera EJ, Brugel TA, VanRens JC, Laufersweiler MJ, Maier JA, Sabat MP, Golebiowski A, Easwaran V, Webster ME, De B, Zhang G

Development of new pyrrolopyrimidine-based inhibitors of Janus kinase 3 (JAK3).

Bioorg Med Chem Lett. 2007 Mar 1;17(5):1250-3. Epub 2006 Dec 9.

PubMed ID

17189692 [ View in PubMed

]

Abstract

A new class of bicyclic pyrrolopyrimidine-based Janus kinase 3 (JAK-3) inhibitors are described. Many of these inhibitors showed low nanomolar activity against JAK-3.

DrugBank Data that Cites this Article

Binding Properties

Drug	Target	Property	Measurement	pH	Temperature (°C)
Tofacitinib	Tyrosine-protein kinase JAK2	IC 50 (nM)	11	N/A	N/A	Details
Tofacitinib	Tyrosine-protein kinase JAK3	IC 50 (nM)	13	N/A	N/A	Details